• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Renal and Bladder Disorders
    37 Drugs classified under this therapeutic system


    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Alkasolve
    SAM-ON
    OTC
    full basket chart
    Multiple ingredients
    Alkasolve

    Alkalinizing Agent. Potassium Citrate 330 mg, Sodium Citrate 300 mg.
    COAT. TABS: 180. 2 tabs. 3 x dly. 1/2 hr. aft. meals.
    Urin. alk. in pyelit., pyuria, urethrit.,
    acidosis assoc. with diabetes.

    Aranesp
    Amgen
    RX
    partial basket chart
    Aranesp

    Recombinant Human Erythropoietin. Darbepoetin Alfa 10, 20, 30, 40, 50, 60, 80, 100, 150, 300, 500 mcg.
    PREFILL. SYRINGES (for single use only,
    with/out automat. needle guard): 4 x 10
    μg; 20 μg; 30 μg; 40 μg; 50 μg; 60 μg; 80
    μg; 100 μg, 150 μg; 1 x 300 μg, 500 μg.
    For I.V. and S.C. admin. Similar efficacy
    in I.V. and S.C. admin.
    PREFILL. PEN (SureClick) (single use
    only): 1 x 20 μg, 40 μg, 60 μg, 80 μg, 100
    μg,150 μg, 300 μg, 500 μg. S.C. admin
    only.
    Tmt. anem. assoc. with chron. ren. fail. in
    adults and pediatric subjects 11 yrs of
    age and over. Aranesp 150, 300, 500 -
    also tmt. anem. in adult cancer pts. with
    non-myeloid malignancies receiv.
    chemother.

    Betmiga
    Astellas
    RX
    not in the basket chart
    Betmiga

    Urinary Antispasmodic. Mirabegron 25 mg, 50 mg.
    PROLONG REL. TABS.: 30×25, 50 mg.
    Adult. (include. elder. pts.) 50 mg once
    daily with/without food.
    Sympt. tmt. of urgency, incr. micturition
    freq. and/or urgency incont. as may occur
    in adult pts. with OAB syndr.
    C/I: Hypersens.

    Binocrit
    Novartis
    RX
    partial basket chart
    Binocrit

    Recombinant Human Erythropoietin. Epoeitin Alpha 1,000 IU/0.5 ml, 2,000 IU/1 ml, 3,000 IU/0.3 ml, 4,000 IU/0.4 ml, 5,000 IU/0.5 ml, 6,000 IU/0.6 ml, 8,000 IU/0.8 ml, 10,000 IU/1 ml, 20,000 IU/0.5 ml, 30,000 IU/0.75 ml, 40,000 IU/1 ml.
    Prefilled syringes (ready to
    use):1,6×1000IU/0.5ml, 2000IU/1ml,
    3000IU/0.3ml, 4000IU/0.4ml,
    5000IU/0.5ml, 6000IU/0.6ml,
    8000IU/0.8ml, 10000IU/1ml,
    20000IU/0.5ml, 30000IU/0.75ml &
    40000IU/1ml.
    Tmt. and dosage has to be initiated
    and adjust. individ. for each pt. accord.
    to the med. condit.
    Tmt. of symptom. anaemia assoc.with
    chron.renal fail.(CRF) in adult and
    paediatric pts.:- Tmt. of anaemia assoc.
    with chron. ren. fail.in paed. and adult pts.
    on haemodialysis and adult pts. on
    periton. dialysis.- Tmt. of sev. anaemia of
    renal origin accomp. by clin. sympt. in
    adult pts. with ren. insuffic. not yet
    undergoing dialysis. Tmt. of anaemia and
    reduct. of transfus. requirem. in adult pts.
    receiv. chemother. for solid tumour.,
    malign. lymphoma or multiple myeloma,
    and at risk of transfus. as assessed by the
    patient’s gener. status (e.g. cardiovascular
    status, pre existing anaemia at the start of
    chemother.). Binocrit can be used to
    increase the yield of autologous blood from pts. in a predonation programme. Its
    use in this indicat. must be balanced
    against the reported risk of thromboemb.
    events. Tmt. should only be given to noniron
    defic. pts. with moder. anaem.
    (haemoglobin (Hb) 10 13 g/dl (6.2 8.1
    mmol/l)), if blood saving procedur. are not
    available or insuffic. when the scheduled
    major elect. surg. requires a large volume
    of blood (4 or more units of blood for
    females or 5 or more units for males). The
    drug can be used to reduce exposure to
    allogeneic blood transfus. in adult non
    iron defic. pts. prior to major elective
    orthopaedic surg., having a high perceived
    risk for transfus. complicat. Use should be
    restricted to pts. with moder. anaemia (e.g.
    Hb 10 13 g/dl) who do not have an
    autolog. predonation programme
    available and with an expect. blood loss of
    900 to 1800 ml.
    C/I: Hypersens., pts. who develop PRCA
    follow. tmt. with any erythropoietin
    should not receive this drug or any other
    erythropoietin.


    Other therapeutic systems under Genito-Urinary System

    CLOSE